Hirotake Kasuga

Hirotake Kasuga

Auto-generated profile, based on publicly available information

Hirotake Kasuga

Department of Nephrology, Nagoya Kyoritsu Hospital, Nagoya, Japan

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Journal of Cardiology
Verified
Journal Article
Closed access
HTHiroshi Takahashi
Hiroshi Takahashi
YIYasuhiko Ito
Yasuhiko Ito
HIHideki Ishii
Hideki Ishii
TAToru Aoyama
Toru Aoyama
DKDaisuke Kamoi
Daisuke Kamoi
YYYukio Yuzawa
Yukio Yuzawa

1 January 2008 in Circulation Journal
Verified
Journal Article
Open access
PDF file
TAToru Aoyama
Toru Aoyama
HIHideki Ishii
Hideki Ishii
TTTakanobu Toriyama
Takanobu Toriyama
HTHiroshi Takahashi
Hiroshi Takahashi
HKHirotake Kasuga
Hirotake Kasuga
TMToyoaki Murohara
Toyoaki Murohara
Background Accelerated atherosclerosis is a major risk for long-term survivors receiving hemodialysis (HD), with coronary events being the leading cause of mortality. Methods and Results A total of 88 consecutive patients on HD (121 lesions) who underwent percutaneous coronary intervention (PCI) with sirolimus-eluting stents (SES) were compared with 78 patients on HD (95 lesions) who received bare metal stents (BMS) in the preceding 1 year. The primary endpoint was angiographic restenosis defined as ≥50% diameter stenosis at 6-8 months follow-up after PCI. The angiographic restenosis rate at follow-up was 22.2% in the SES group and 24.4% in the BMS group. No difference was detected in the restenosis rate between the 2 groups (p=0.73). When including both HD and non-HD patients, the independent predictors for restenosis after SES implantation were treatment with HD (hazard ratio (HR) 3.12; 95% confidence interval (CI) 1.23-7.95; p=0.016), incidence of hyperlipidemia (HR 3.93; 95%CI 1.12-13.7; p=0.032), coronary calcification (HR 2.78; 95%CI 1.12-6.91; p=0.027), and implantation of multi-stents (HR 4.14; 95%CI 1.70-10.1; p=0.0017). Conclusions Even if treated with SES, patients with end-stage renal failure on HD are at high risk of restenosis after PCI. (Circ J 2008; 72: 56 - 60)

1 October 2010 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
SYShigeki Yamada
Shigeki Yamada
HIHideki Ishii
Hideki Ishii
HTHiroshi Takahashi
Hiroshi Takahashi
TAToru Aoyama
Toru Aoyama
YMYasuhiro Morita
Yasuhiro Morita
TMToyoaki Murohara
Toyoaki Murohara
Background and objectives: Cardiac failure is directly affected by left ventricular (LV) dysfunction, and particularly LV systolic dysfunction is strongly associated with survival in ESRD patients. The aim of this study was to determine the prognostic value of reduced LV ejection fraction (LVEF) measured at the time of initiation of hemodialysis (HD) in incident HD patients. Design, setting, participants, & measurements: 1254 consecutive ESRD patients who electively started HD therapy were screened by echocardiography within 1 month after its inception. They were divided into five groups according to LVEF levels with a decrease of 0.1 each and were followed up for up to 7 years. Survival was examined with the Kaplan-Meier method and compared using the log-rank test. Results: Among the 1254 patients, LVEF levels ≥0.6, 0.5 to 0.6, 0.4 to 0.5, 0.3 to 0.4, and <0.3 were seen in 842 (67.1%), 247 (19.7%), 107 (8.5%), 41 (3.3%), and 17 (1.4%) patients, respectively. On Kaplan-Meier analysis, 7-year event-free rates from cardiovascular death were 84.2, 83.7, 73.6, 59.4, and 30.9% in order of groups with decreasing LVEF of 0.1 each, respectively. Seven-year event-free rates from all-cause death were 69.2, 61.7, 57.1, 45.9, and 23.1% in the respective groups. Even after adjustment for other risk factors, decreasing LVEF was a strong independent predictor for cardiovascular death. Conclusions: Reduced LVEF on starting HD therapy could stratify risk of cardiovascular and all-cause mortality in ESRD patients. Screening by echocardiography at start of HD therapy might be recommended to predict prognosis in patients with ESRD.

1 May 2014 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
YIYasuhiko Ito
Yasuhiko Ito
MMMasashi Mizuno
Masashi Mizuno
YSYasuhiro Suzuki
Yasuhiro Suzuki
HTHirofumi Tamai
Hirofumi Tamai
THTakeyuki Hiramatsu
Takeyuki Hiramatsu
SMSeiichi Matsuo
Seiichi Matsuo
ESRD treated with dialysis is associated with increased left ventricular hypertrophy, which, in turn, is related to high mortality. Mineralocorticoid receptor antagonists improve survival in patients with chronic heart failure; however, the effects in patients undergoing dialysis remain uncertain. We conducted a multicenter, open-label, prospective, randomized trial with 158 patients receiving angiotensin-converting enzyme inhibitor or angiotensin type 1 receptor antagonist and undergoing peritoneal dialysis with and without (control group) spironolactone for 2 years. As a primary endpoint, rate of change in left ventricular mass index assessed by echocardiography improved significantly at 6 (P=0.03), 18 (P=0.004), and 24 (P=0.01) months in patients taking spironolactone compared with the control group. Rate of change in left ventricular ejection fraction improved significantly at 24 weeks with spironolactone compared with nontreatment (P=0.02). The benefits of spironolactone were clear in patients with reduced residual renal function. As secondary endpoints, renal Kt/V and dialysate-to-plasma creatinine ratio did not differ significantly between groups during the observation period. No serious adverse effects, such as hyperkalemia, occurred. In this trial, spironolactone prevented cardiac hypertrophy and decreases in left ventricular ejection fraction in patients undergoing peritoneal dialysis, without significant adverse effects. Further studies, including those to determine relative effectiveness in women and men and to evaluate additional secondary endpoints, should confirm these data in a larger cohort.

1 October 2011 in Clinical and Experimental Nephrology
Verified
Journal Article
Closed access
PDF file
MMMasashi Mizuno
Masashi Mizuno
YIYasuhiko Ito
Yasuhiko Ito
ATAkio Tanaka
Akio Tanaka
YSYasuhiro Suzuki
Yasuhiro Suzuki
HHHideki Hiramatsu
Hideki Hiramatsu
SMSeiichi Matsuo
Seiichi Matsuo

18 July 2012 in American Journal of Nephrology
Verified
Journal Article
Closed access
PDF file
RTRyo Takahashi
Ryo Takahashi
YIYasuhiko Ito
Yasuhiko Ito
HTHiroshi Takahashi
Hiroshi Takahashi
HIHideki Ishii
Hideki Ishii
HKHirotake Kasuga
Hirotake Kasuga
SMSeiichi Matsuo
Seiichi Matsuo
Background: Protein-energy wasting and chronic inflammation are prevalent in patients with end-stage renal disease (ESRD). We investigated the combination of serum albumin, C-reactive protein (CRP) and body mass index (BMI) at initiation of hemodialysis therapy as a predictor of all-cause and cardiovascular disease (CVD) mortality in Japanese ESRD patients. Methods: A total of 1,228 consecutive Japanese ESRD patients on hemodialysis therapy were enrolled and followed for up to 10 years. Patients were divided into quartiles according to levels of albumin, CRP and BMI. Furthermore, to clarify the joint role of these factors, albumin 4.0 mg/l and BMI <19.6 were defined as risk factors using receiver operating characteristic analysis; thereafter, patients were divided into groups according to the positive number of these factors. Results: Adjusted hazard ratios (HRs) for lower serum albumin, elevated CRP and lower BMI for 10-year all-cause mortality were 1.97, 3.13 and 2.61, respectively. Regarding the combination of these variables, adjusted HRs for mortality were 2.31, 4.28 and 8.07, respectively, in patients having any one factor, any two factors and all three factors. The C-index for an established risk model with these three positive markers was the most accurate for predicting mortality (0.768), as compared to other models with one or two markers. Similar results were seen for CVD mortality. Conclusions: Serum albumin, CRP and BMI at the start of hemodialysis therapy were able to individually stratify the risk of long-term mortality in ESRD patients. Furthermore, a combination of these variables could more accurately predict mortality.